C-reactive protein and cardiovascular disease: a review of risk prediction and interventions (Q28192240)

Prevalence of nonfatal coronary heart disease among American adults

Europe PubMed Central

title

C-reactive protein and cardiovascular disease: a review of risk prediction and interventions (English)

0 references

main subject

cardiovascular disease

1 reference

1

Sarah de Ferranti

0 references

author name string

Nader Rifai

series ordinal

2

0 references

language of work or name

English

0 references

publication date

March 2002

0 references

published in

Clinica Chimica Acta

0 references

volume

317

0 references

issue

1-2

0 references

page(s)

1-15

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Range of serum cholesterol values in the population developing coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Acute-phase proteins and other systemic responses to inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Complement activation by C-reactive protein complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Inflammation in cardiovascular disease: cart, horse, or both?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Direct proinflammatory effect of C-reactive protein on human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Enhanced inflammatory response in patients with preinfarction unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Independent prognostic value of elevated C-reactive protein in unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Comparison of the prognostic value of C-Reactive protein and troponin I in patients with unstable angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Elevation of C-reactive protein in "active" coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Infections, inflammation, and the risk of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Hormone replacement therapy, inflammation, and hemostasis in elderly women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Hormone replacement therapy and increased plasma concentration of C-reactive protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Blood pressure and inflammation in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Retinal vein occlusion: C-reactive protein and arterial hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Raised C-reactive protein levels in serum from smokers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Elevated C-reactive protein levels in overweight and obese adults

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

inferred from DOI database lookup

7 January 2021

based on heuristic

C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

C-Reactive Protein in Offspring Is Associated With the Occurrence of Myocardial Infarction in First-Degree Relatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

10.1016/S0009-8981(01)00797-5

7 January 2021

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

11814453

1 reference

Consolidated OpenCitations Corpus – April 2017